Abstract
e13026Background: Palbociclib was the first CDK 4/6 inhibitor approved in Argentina for HR+/HER2- advanced/ metastatic breast cancer (ABC/ MBC) in combination with letrozole or fulvestrant. However, no data exists on real world outcomes associated with palbociclib in Argentina. Ibrance Real World Insights (IRIS) is a multi-country study aimed to describe treatment patterns and clinical outcomes of patients receiving palbociclib in real world clinical practices. Methods: Medical records of adult female patients with HR+/HER2- ABC/ MBC who received palbociclib + letrozole or fulvestrant were reviewed by their treating physicians. Data on demographic and clinical characteristics, treatment patterns, and clinical outcomes were extracted. Progression free rate and survival at 6 and 12 months were estimated via Kaplan-Meier analysis. Results: 162 patient records were abstracted by 41 physicians. Approximately, 44% of physicians were from public practices. The mean (SD) age of patients at palbociclib initiation ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
